Download UH Case Medical Center first in Ohio to implant new ventricular

Date
Contacts
Phone
June 3, 2015
Mike Ferrari
216.844.7239
News Release
Department of Marketing and
Communications
3605 Warrensville Center Road
Shaker Heights, OH, 44122
UH Case Medical Center first in Ohio to implant new ventricular assist device
Giant mobile learning lab coming to campus on June 5
CLEVELAND — University Hospitals Case Medical Center physicians in the Harrington Heart
& Vascular Institute were the first in the state of Ohio to implant a revolutionary device to treat
right ventricular heart disease.
The Impella RP, made by Abiomed, addresses an unmet need of treating right heart failure in the
setting of right ventricular (RV) infarction or after complex heart surgery including heart
transplant. The device allows the right side of the heart to recover without the upfront need for
invasive surgical intervention.
University Hospitals’ multidisciplinary team including interventional cardiologist M. Najeeb
Osman, MD, Chief, Cardiac Rehabilitation and Intensive Care Unit and Assistant Clinical
Professor of Medicine at Case Western Reserve University School of Medicine and cardiac
surgeon Benjamin Medalion, MD, Clinical Associate Professor of Surgery at the School of
Medicine, led a collaborative heart team in the catheterization lab during the first implantation at
UH.
“The device sits inside the heart and takes blood from the right atrium and pushes it through the
right side of the heart to the pulmonary artery, assisting the ailing right ventricle in its pumping
function,” said Sahil Parikh, MD, Director of the UH Harrington Heart & Vascular Institute
Center for Research and Innovation and Assistant Professor of Medicine at the School of
Medicine. “This is an incredible breakthrough in treatment. It allows us to provide patients who
were once untreatable with a new non- surgical option that serves as a bridge to transplant and/or
recovery.”
Traditional treatments for right ventricular issues are extremely limited. Many patients who
experience RV dysfunction have exhausted interventional options and require invasive surgery
but are at high risk for complications.
Right ventricular dysfunction has largely been under appreciated or under treated despite its
importance in such severe conditions as cardiogenic shock largely due to the inability to support
these patients without complex and highly invasive therapies. Cardiogenic shock limits the heart
from pumping enough blood to vital organs such as the brain, lungs, liver and kidneys. Patients
with severe RV dysfunction are at high risk for death, and open heart surgery and drug therapies
have had limited success.
HCS-CC00870 rA
The Impella RP device allows for minimally invasive implantation done in the catheterization
lab (about an hour procedure) and is effectively serving as a successful bridge to transplant
and/or recovery and may get the patient through an acute phase of the illness.
“This is an invaluable and potentially lifesaving tool for patients with advanced heart failure with
acute right heart failure,” Dr. Osman said. “This new device will help us stabilize patients and
buy precious time that enables them to be potential transplant candidates.”
UH now offers the full spectrum of Impella pumps. Abiomed's portfolio of heart support and
recovery products and services offer health care professionals an array of choices across a broad
clinical spectrum. The Impella heart pump family has supported over 30,000 patients in the
United States.
Mobile lab slated for UH Campus
UH will participate in the Abiomed Mobile Learning Lab (MLL) program on June 5. The
Abiomed Mobile Learning Lab is a highly interactive, facilitated learning experience that is
brought directly to the hospital to train the hospital staff on the Impella heart pump, one of the
newest, minimally invasive heart technologies. The flagship Impella device, the Impella 2.5,
recently received FDA approval to treat high-risk percutaneous coronary intervention (PCI)
patients. The procedure, Protected PCI, is offered at UH.
The Mobile Learning Lab offers cardiologists, nurses and cath lab staff at UH Case Medical
Center a convenient opportunity to learn about the new technologies. The Mobile Learning Lab
contains various Impella simulators, animations and key information, which are all presented by
a team of Abiomed trainers.
“Our community of patients and partners deserve the best therapies available. Our participation
with the mobile learning lab will ensure that our staff is highly trained to effectively utilize the
most innovative health care technology solutions available for our patients,” said Dr. Parikh.
About University Hospitals
University Hospitals, the second largest employer in Northeast Ohio with 25,000 employees, serves the needs of
patients through an integrated network of 15 hospitals, 29 outpatient health centers and primary care physician
offices in 15 counties. At the core of our $3.5 billion health system is University Hospitals Case Medical Center,
ranked among America’s 50 best hospitals by U.S. News & World Report in all 12 methodology-ranked specialties.
The primary affiliate of Case Western Reserve University School of Medicine, UH Case Medical Center is home to
some of the most prestigious clinical and research centers of excellence in the nation, including cancer, pediatrics,
women's health, orthopaedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health,
transplantation and genetics. Its main campus includes UH Rainbow Babies & Children's Hospital, ranked among
the top children’s hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and
UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western
Reserve University. For more information, go to www.uhhospitals.org
###